MBX Biosciences Inc. (NASDAQ:MBX) is one of the stocks that will double in 2026. On December 4, Goldman Sachs initiated coverage of MBX Biosciences with a Sell rating and $18 price target. The key ...

MBX shares are currently trading at $28.67, with analysts maintaining a Strong Buy consensus and a high target of $80, according to InvestingPro data. The price target increase comes after MBX’s ...

NEW YORK, Dec. 16, 2025 /PRNewswire/ -- Medivis Inc., a pioneer in surgical intelligence, today announced it has received FDA 510(k) clearance for its Cranial Navigation platform – making it the world ...

The rise of GPS vulnerability is putting more resilient, atom-based navigational tools on the map. In late September, a Spanish military plane carrying the country’s defense minister to a base in ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

MBX Capital is an early-stage venture capital firm with more than $100M in cumulative capital commitments, investing in founders advancing breakthroughs across deep health, including novel ...

Today, external ventricular drains (EVDs) are misplaced at rates reported as high as 30%, often leading to repeated passes, patient harm, and delayed critical care. By providing real-time, AR-guided ...

Salt Lake City, Utah, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Novarad Corporation, a global leader in medical imaging and immersive augmented reality surgical navigation, today announced that the United ...

This is read by an automated voice. Please report any issues or inconsistencies here. The actor and cast member of ‘The Real Housewives of Beverly Hills’ discusses the latest season, the presidential ...

Good morning, everyone. Thanks for joining us today. We have Microbix here to talk about their Q4 and Year-End Results for 2025. Before we get into those, I don't believe we're going to work off our ...